Orion Portfolio Solutions LLC acquired a new stake in shares of Zai Lab Limited (NASDAQ:ZLAB - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 11,956 shares of the company's stock, valued at approximately $313,000.
Several other large investors also recently modified their holdings of ZLAB. Pictet Asset Management Holding SA bought a new position in Zai Lab during the 4th quarter valued at about $31,000. US Bancorp DE raised its stake in shares of Zai Lab by 1,671.9% in the fourth quarter. US Bancorp DE now owns 5,865 shares of the company's stock valued at $154,000 after acquiring an additional 5,534 shares during the last quarter. Y Intercept Hong Kong Ltd acquired a new position in shares of Zai Lab in the 3rd quarter worth approximately $225,000. China Universal Asset Management Co. Ltd. grew its position in Zai Lab by 15.7% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,061 shares of the company's stock worth $290,000 after acquiring an additional 1,502 shares during the last quarter. Finally, Point72 Asset Management L.P. acquired a new stake in Zai Lab during the 3rd quarter valued at $325,000. 41.65% of the stock is currently owned by institutional investors.
Insider Activity at Zai Lab
In other news, insider Rafael Amado sold 3,000 shares of Zai Lab stock in a transaction on Monday, March 17th. The shares were sold at an average price of $38.41, for a total transaction of $115,230.00. Following the transaction, the insider now directly owns 30,834 shares of the company's stock, valued at $1,184,333.94. This trade represents a 8.87 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Ying Du sold 50,000 shares of the business's stock in a transaction on Friday, February 28th. The shares were sold at an average price of $34.47, for a total transaction of $1,723,500.00. Following the completion of the transaction, the chief executive officer now directly owns 494,117 shares of the company's stock, valued at $17,032,212.99. This trade represents a 9.19 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 138,744 shares of company stock worth $4,685,294. 13.88% of the stock is owned by insiders.
Zai Lab Price Performance
Shares of NASDAQ ZLAB traded down $1.28 during mid-day trading on Tuesday, hitting $30.24. The company's stock had a trading volume of 332,426 shares, compared to its average volume of 827,607. Zai Lab Limited has a one year low of $13.48 and a one year high of $39.77. The company's fifty day simple moving average is $32.83 and its 200-day simple moving average is $29.17. The stock has a market cap of $3.31 billion, a price-to-earnings ratio of -10.89 and a beta of 1.09.
Zai Lab (NASDAQ:ZLAB - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.61) by ($0.19). The business had revenue of $109.07 million during the quarter, compared to the consensus estimate of $110.15 million. Zai Lab had a negative net margin of 76.14% and a negative return on equity of 36.97%. On average, sell-side analysts predict that Zai Lab Limited will post -2.58 EPS for the current year.
Analyst Upgrades and Downgrades
A number of equities analysts have commented on the company. JPMorgan Chase & Co. boosted their price objective on Zai Lab from $44.00 to $51.00 and gave the stock an "overweight" rating in a research note on Thursday, March 13th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Zai Lab in a research report on Thursday, March 27th. Bank of America restated a "neutral" rating and issued a $36.10 price objective (up previously from $29.00) on shares of Zai Lab in a research report on Monday, March 3rd. Finally, Scotiabank began coverage on shares of Zai Lab in a research report on Friday, March 7th. They issued a "sector outperform" rating and a $55.00 price objective for the company.
Get Our Latest Analysis on Zai Lab
Zai Lab Company Profile
(
Free Report)
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.
Featured Articles
Before you consider Zai Lab, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zai Lab wasn't on the list.
While Zai Lab currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
